Have the explicitly said "Mesoblast will now focus on its original strategy to first gain pediatric approval for RYONCIL, followed by label extension in the larger adult" before? Rather confident.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.020(1.95%) |
Mkt cap ! $1.193B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.07 | $1.02 | $7.487M | 7.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 39700 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 86509 | 6 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
0.020 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| $1.02 | $1.07 | $1.02 | 1379563 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| MSB (ASX) Chart |